.You are here: Home > Postdoctoral scientist,gene regulatory mechanisms and diabetes Postdoctoral scientist, gene regulatory mechanisms and diabetes The Institute The Centre for Genomic Regulation (CRG) is an international biomedical research institute of excellence, based in Barcelona, Spain, with more than 400 scientists from 44 countries.
The CRG is composed of an interdisciplinary, motivated and creative scientific team which is supported both by a flexible and efficient administration and by high-end and innovative technologies.
We are seeking a motivated postdoctoral scientist interested in dissecting genome regulatory mechanisms underlying human diabetes.
The successful applicant will develop cell-based model systems such as human stem cell-derived beta cells, using single cell genomic read-outs, and will explore poorly understood genome regulatory mechanisms.
The work will be performed within a multidisciplinary lab located in the CRG.
About the lab The Regulatory Genomics and Diabetes lab aims to uncover genetic mechanisms causing diabetes mellitus, and to develop therapeutic avenues.
The group is particularly interested in understanding how genomic information is used to direct cell-specific gene expression, and to pinpoint gene regulatory defects underlying human disease.
The team brings together diverse expertise, ranging from work with mutant stem cell-derived beta cell organoids, engineered mouse models, single cell epigenomics, large-scale genetic screens, statistical genetics, and the integration of genetic and regulatory data.
This multidisciplinary approach gives us unique opportunities to engage in collaborative projects that combine experimental and computational methods.
The lab encourages wet lab scientists to engage in their own data analysis and provides a supportive environment to this end.
The group is funded by European Research Council, the Spanish Ministry of Science and Innovation, Generalitat de Catalunya, an AXA chair, European Foundation for the Study of Diabetes, the Marie Sklodowska-Curie Actions program, and a CIBERDEM diabetes network.
The lab forms part of international consortia focused on advancing research in regulatory genomics, single cell genomics, and human genetics.
Recent studies from the lab include: A lineage-specific gene transcription and splicing hierarchy that is disrupted in type 2 diabetes (In review) Large-scale discovery of molecular targets for precision treatment of HNF1A-deficient diabetes (In review).
Transcription regulation by long non-coding RNAs and their disease relevance (Nat Rev Mol Cell Biol, 2024).
HASTER lncRNA promoter is a cis-acting transcriptional stabilizer of HNF1A (Nat Cell Biol 2022).
Pancreas agenesis mutations disrupt a lead enhancer controlling a developmental enhancer cluster.
Human pancreatic islet 3D chromatin architecture provides insights into the genetics of type 2 diabetes (Nat Genet 2019)